Sanofi reports EPS at €1.06 in Q4, down 15% YoY

Wednesday, 07. February 2018 07:44

French pharmaceutical giant Sanofi S.A. reported on Wednesday its earnings per share (EPS) for the last quarter of 2017 stood at €1.06, down 15.2% compared to the same period a year ago. The company said its net sales for the quarter were €8.7 billion, declining 2% year on year. The firm's net income came to €129 million in the last three months of 2017, plunging 83.7% year on year.

Meanwhile, Sanofi's EPS for the whole of 2017 amounted to €5.54, falling 2.5% compared to the full-year results recorded in 2016 while its net sales for this year stood at €35 billion, improving 3.6% compared to the previous year. Pharma giant's full-year net income was €8.4 billion, rising 83.3% compared to the whole of 2016.

"Recently, we announced a series of strategic steps - we are obtaining the global rights to fitusiran and plan to acquire Bioverativ and Ablynx - which will establish Sanofi as a new global leader in rare blood disorders. Additionally, these actions will further strengthen our pipeline and provide us with the powerful new Nanobody® technology platform. Overall, after a period of significant reshaping since 2015, we are positioned to drive growth in 2018," said Sanofi's CEO Olivier Brandicourt.

Following the release of corporate results, Sanofi shares gained 0.55% in the premarket trade on Wall Street.

Related Links: Sanofi S.A.Sanofi S.A.
Breaking the News / VK